Drugs Targeting Epithelial–Mesenchymal Transition Molecules for Treatment of Lichen Planopilaris
May 2022
in “
Clinical and experimental dermatology
”
TLDR Drugs targeting EMT molecules show promise for treating lichen planopilaris.
Lichen planopilaris (LPP) is a subtype of primary cicatricial alopecia that causes permanent hair loss by destroying hair follicles. Recent research has identified that follicular stem cells in LPP undergo epithelial-mesenchymal transition (EMT). This study aimed to find drugs targeting EMT molecules to treat LPP. Eight molecules and 15 drugs were identified, with four drugs (pioglitazone, tofacitinib, barcitinib, and apremilast) previously reported in individual cases or series but lacking controlled studies. The paper highlights the potential of these EMT-targeting drugs for future clinical trials in LPP treatment.